Volume | 175,454 |
|
|||||
News | - | ||||||
Day High | 1.46 | Low High |
|||||
Day Low | 1.388 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Spero Therapeutics Inc | SPRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.42 | 1.388 | 1.46 | 1.43 | 1.42 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
656 | 175,454 | $ 1.43 | $ 250,961 | - | 0.99 - 1.995 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:18:40 | formt | 7,548 | $ 1.4115 | USD |
Spero Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
77.03M | 53.87M | - | 103.78M | 22.81M | 0.42 | 3.38 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spero Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.50 | 1.55 | 1.37 | 1.42 | 229,588 | -0.0885 | -5.90% |
1 Month | 1.74 | 1.81 | 1.37 | 1.61 | 229,564 | -0.3285 | -18.88% |
3 Months | 1.53 | 1.89 | 1.33 | 1.66 | 335,613 | -0.1185 | -7.75% |
6 Months | 1.03 | 1.89 | 0.99 | 1.53 | 248,313 | 0.3815 | 37.04% |
1 Year | 1.69 | 1.995 | 0.99 | 1.52 | 274,306 | -0.2785 | -16.48% |
3 Years | 13.58 | 19.87 | 0.6801 | 2.36 | 960,991 | -12.17 | -89.61% |
5 Years | 12.33 | 23.639 | 0.6801 | 3.56 | 641,635 | -10.92 | -88.55% |
Spero Therapeutics Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |